Vivek Ramaswamy Net Worth (Money & Salary)

Vivek Ramaswamy Net Worth (Money & Salary)

Vivek Ramaswamy, an American tycoon, pioneer, and writer, possesses a wealth of $800 million. As detailed in the following paragraphs, Vivek Ramaswamy amassed his prosperity through investments in biotechnology and finance. He gained national prominence in August 2023 as a Republican contender for the presidency. On August 23, 2023, Vivek emerged as the dominant figure in the inaugural Republican debate.

The bulk of Vivek’s fortune originates from his ownership of 7% in a firm known as Roivant Sciences (further elaborated on below). In 2020, Roivant vended five medications and a 5% share to a Japanese pharmaceutical entity for $3 billion. Consequently, Vivek pocketed $176 million in 2020. According to public revelations, Vivek garnered $260 million between 2014 and 2022 alone in salaries, perks, and investments.

Roivant underwent an initial public offering through a SPAC consolidation in early 2021. Upon finalizing the merger, Roivant’s value stood at $7.3 billion. As such, Vivek’s 8% stake was valued at approximately $511 million. By mid-August 2023, during his participation in the Republican debate, Roivant commanded a market cap of $8.56 billion. Hence, Vivek’s 7% stake was valued at roughly $600 million. Despite what you may have read on alternate platforms, Vivek Ramaswamy has never reached the status of a billionaire in terms of net worth.

Vivek also possesses a one-third stake in Strive Asset Management, an index fund provider. Presently, Strive manages assets exceeding $500 million. In mid-2023, Strive’s valuation reached $300 million, thus enhancing Vivek’s wealth by $100 million.

Before leaping into the spotlight as a conservative presidential contender, Vivek was notably recognized for establishing a pharmaceutical company called Roivant Sciences. Roivant Sciences acquires neglected and discarded drugs for advancement and ideally, approval from the FDA. For instance, in 2015, a Roivant subsidiary named Axovant paid $5 million to procure an abandoned Alzheimer’s medication from GlaxoSmith Kline. Two years later, Axovant amassed over $360 million in what was then the most substantial biotech IPO ever. The company momentarily attained a peak valuation of $2.5 billion. Regrettably, Axovant’s primary asset was ineffective in treating Alzheimer’s, leading to the company’s market value plummeting to $20 million before its closure. Vivek relinquished his role as Roivant’s CEO in 2021 and promptly co-founded Strive Asset Management.

Ramaswamy authored the books “Woke, Inc.: Inside Corporate America’s Social Justice Scam” (2021) and “Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence” (2022). “Politico” hailed him as “one of the intellectual originators of the anti-woke movement.” In 2016, Vivek was ranked #24 on a list of “America’s Wealthiest Entrepreneurs Under 40” with a net worth of $600 million.

In February 2023, Ramaswamy declared his candidacy for the Republican nomination in the 2024 presidential election, stating, “I am not just initiating a political campaign, but instigating a cultural revolution to establish a novel American Dream—one centered not solely on monetary gains but on the unwavering pursuit of distinction.” By August 2023, Vivek had qualified to partake in the initial Republican debate of the 2024 campaign. Ultimately, Vivek emerged triumphant in the debate; however, his statements generated considerable controversy. For instance, he outright dismissed climate change as a “deception.”

Younger Days

Vivek Ganapathy Ramaswamy was born on August 9, 1985, in Cincinnati, Ohio. His mother, a geriatric psychiatrist named Geeta Ramaswamy, and his father, Vivek Ganapathy, an engineer at General Electric, emigrated from Vadakkencherry, Palakkad, Kerala, India, to the U.S.

Ramaswamy attended St. Xavier High School, a Jesuit institution, where he graduated as the top student and excelled in tennis, achieving national recognition. He graduated summa cum laude from Harvard College with a Bachelor of Arts degree in biology in 2007. During his college years, he joined the Phi Beta Kappa fraternity. Vivek was honored with the Bowdoin Prize for Natural Sciences for his thesis on “the moral dilemmas arising from the creation of human-animal hybrids,” subsequently published by “The Boston Globe” and “The New York Times.”

In 2011, The Paul & Daisy Soros Fellowships for New Americans granted Ramaswamy a fellowship to support his pursuit of a Juris Doctor degree from Yale University. He completed his law studies at Yale Law School in 2013.

Commencement of Career

In 2007, Vivek established the tech venture Campus Venture Network alongside Travis May. This entity provided networking tools and software to college-based entrepreneurs, operating under the website StudentBusinesses.com. Ramaswamy and May divested the company to the Ewing Marion Kauffman Foundation in 2009.

From 2007 to 2014, Vivek served at QVT Financial, where, as a partner and biotech portfolio co-manager, he amassed a total of $7 million in remuneration over the span of seven years.

Roivant Sciences

In 2014, Vivek laid the foundation for Roivant Sciences, a pharmaceutical establishment committed to “developing and providing medications to patients in a quicker and more efficient manner.” Roivant typically acquires pharmaceutical drugs that have undergone a development pause due to various reasons. Acquiring these drugs for a fraction of their cost, Roivant invests additional resources to advance development with the aim of obtaining FDA authorization.

In 2017, Roivant secured $1.1 billion in funding through an investment round spearheaded by SoftBank.

In 2020, Roivant transacted five of its medications to Sumitomo Dainippon, a Japanese pharmaceutical corporation, for $3 billion. Concurrently, Sumitomo procured a 5% stake in Roivant. This transaction saw Vivek earning $176 million in 2020.

Ramaswamy relinquished his position as CEO of Roivant in January 2021.A couple of months later Roivant accepted a SPAC merger in a transaction that ultimately appraised the firm at $7.3 billion. By then, Vivek’s 7% interest in Roivant was valued at $511 million.

Axovant Sciences

In 2015, a Roivant subsidiary known as Axovant Sciences raised $362 million in what became the most significant biotech IPO to date. The primary asset of Axovant was an Alzheimer’s pharmaceutical named Intepirdine, obtained from GlaxoSmithKline for $5 million. Unfortunately, the Alzheimer’s medication failed to enhance patient results. The day before the announcement of the drug’s failure, Axovant’s market capitalization reached an all-time peak of $2.5 billion. When the news came out in August 2017, Axovant’s stock plummeted by 70%. Shortly after, the firm’s market cap dropped to $500 million. Between December 2017 and April 2022, Axovant’s market cap dwindled from $500 million to $20 million. Axovant is currently in the process of being shut down.

Other Ventures

In 2020, Ramaswamy co-established Chapter Medicare, a Medicare navigation platform, and the subsequent year, he assumed the role of co-founder and executive chairman at Strive Asset Management, headquartered in Ohio. Strive Asset Management received financial backing from notable figures such as J. D. Vance and venture capital entities like BlackRock.

By November 2022, Strive Asset Management’s assets had surpassed $500 million. In mid-2023, Strive was evaluated at $300 million. Vivek possesses a one-third ownership stake in Strive, making his interest valued at $100 million.

Vivek holds anti-ESG (environmental, social, and corporate governance) beliefs, and Strive’s primary aim is to empower ordinary citizens in the American economy by steering companies to prioritize excellence over political agendas.

Presidential Race

In February 2023, Ramaswamy declared his presidential candidacy during an appearance on “Tucker Carlson Tonight.” According to “Politico,” Vivek intends to approach the race with an entrepreneurial mindset, unconventional ideas, and low expectations, with the vision of garnering significant support that would propel him to the presidency.

Books and Appearances

Ramaswamy’s book “Woke, Inc.: Inside Corporate America’s Social Justice Scam” in 2021 attained the second position on “The New York Times” Best Sellers list in the Hardcover Nonfiction category, leading to numerous appearances on talk shows. Ramaswamy has been featured on television programs including “Wake Up America,” “Spicer & Co.,” “Fox and Friends First,” “Fox Report with Jon Scott,” “Fox Files,” “Free Speech Nation,” “Real Time with Bill Maher,” “Fox Business Tonight,” “The Record with Greta Van Susteren,” “Gutfeld!,” and “America Reports.”

Personal Life

Vivek and Apoorva met during their time at Yale University. Apoorva, currently a surgeon and assistant professor at the Ohio State University Wexner Medical Center, and Vivek are proud parents of two sons. In a 2020 essay titled “The Pluralism Within,” Ramaswamy expressed:

“I stand as more than just a man — I am a dedicated father, a faithful husband, and a thankful son. Beyond being a person of color, I am a Hindu, a child of immigrants, an American citizen, and a native of Ohio. While I hold the title of CEO, I also possess the roles of a scientist and an entrepreneur.”

He further revealed that during the period when Apoorva, specializing in airway management, felt obligated to care for Covid patients following the birth of their first son, Vivek assumed the primary caretaker role. Ramaswamy expressed:

“She later contracted the virus in the line of duty and was separated from our family for an extended period.”

Vivek holds fractional ownership in three private aircraft.

Ohio Mansion

In May 2021, Vivek and Apoorva acquired an 11,300 square foot residence in Columbus, Ohio, for $2 million. The expansive mansion, situated on 1.6 acres of meticulously landscaped grounds, is a short 20-minute drive from Ohio State University’s Wexner Medical Center, where Apoorva practices as a surgeon and assistant professor. Additionally, Vivek and Apoorva retain their initial Ohio residence, estimated at about $500,000 in value.

Stats are from 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050.